STAT

Opinion: Medicare’s ‘new technology’ payment plan doesn’t go far enough

We need to establish a system that reimburses hospitals and clinicians for the treatments they provide that is as innovative as the treatments themselves.
A lab tech handles collected blood bags before genetically modifying the patient's immune cells for CAR-T therapy.

It’s a story that’s sadly too familiar to clinicians like me: A middle-aged patient at the prime of life is diagnosed with blood cancer. Despite years of treatment with chemotherapy, stem cell transplants, and a range of medications, the cancer remains and the patient prepares to say his or her goodbyes.

But over the past several years, after decades of challenging scientific work, there is new hope for such patients and their

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

Related Books & Audiobooks